Access to new drugs is becoming increasingly difficult

Switzerland is slipping further down the European rankings when it comes to access to new innovative medicines: according to IQVIA’s EFPIA WAIT Indicator 2024, Switzerland has dropped another place, falling from sixth to seventh. It is particularly alarming that only around half as many new innovative medicines are reimbursed as standard via the specialty list as in Germany – and the trend is downward [1].